News

Oxygenta Pharmaceutical announced that the Annual General Meeting(AGM) of the company will be held on 21 August 2026.

Net Loss of Oxygenta Pharmaceutical reported to Rs 2.10 crore in the quarter ended June 2026 as against net loss of Rs 6.11 crore during the previous quarter ended June 2025. Sales rose 144.55% to Rs 37.00 crore in the quarter ended June 2026 as against Rs 15.13 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales37.0015.13 145 OPM %1.51-45.14 - PBDT-1.88-7.29 74 PBT-2.50-8.14 69 NP-2.10-6.11 66 Powered by Capital Market - Live News

Oxygenta Pharmaceutical has postponed the meeting of the Board of Directors which was scheduled to be held on 25 July 2026. The meeting will now be held on 27 July 2026.

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 25 July 2026.

Net Loss of Oxygenta Pharmaceutical reported to Rs 1.70 crore in the quarter ended March 2026 as against net loss of Rs 2.15 crore during the previous quarter ended March 2025. Sales rose 0.28% to Rs 49.61 crore in the quarter ended March 2026 as against Rs 49.47 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 17.57 crore in the year ended March 2026 as against net loss of Rs 10.30 crore during the previous year ended March 2025. Sales rose 3.37% to Rs 112.98 crore in the year ended March 2026 as against Rs 109.30 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales49.6149.47 0 112.98109.30 3 OPM %0.24-3.40 --13.60-9.15 - PBDT-1.52-3.76 60 -19.86-10.47 -90 PBT-1.28-3.53 64 -22.18-14.08 -58 NP-1.70-2.15 21 -17.57-10.30 -71 Powered by Capital Market - Live News